Vnitr Lek 2012, 58(10):761-764

Febrile pancytopenia and hepatosplenomegaly as leading symptoms of visceral leishmaniasis

P. Polák1,*, R. Svoboda1, P. Kubáčková2, Y. Brychtová3, A. Panovská3, E. Nohýnková4,5, P. Husa1, M. Freibergerová1, R. Pařízková1, M. Šnelerová1, M. Pýchová1, J. Kamelander6
1 Klinika infekčních chorob Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Petr Husa, CSc.
2 Oddělení klinické mikrobiologie FN Brno, pracoviště Bohunice, přednostka prim. MUDr. Alena Ševčíková
3 Interní hematologická a onkologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jiří Mayer, CSc.
4 Klinika infekčních, parazitárních a tropických nemocí 1. lékařské fakulty UK a Nemocnice Na Bulovce Praha, přednosta prof. MUDr. Michal Holub, Ph.D.
5 Národní referenční laboratoř pro diagnostiku tropických parazitárních infekcí Praha, vedoucí RNDr. Eva Nohýnková, Ph.D.
6 Oddělení klinické hematologie FN Brno, přednosta prof. MUDr. Miroslav Penka, CSc.

The authors present a case report of a patient with febrile pancytopenia, hepatosplenomegaly and weight loss as main symptoms of visceral leishmaniasis. Standard treatment regimen with amphothericin B led to relapse of the disease after several weeks. The definitive cure of the disease was achieved with cytostatic miltefosin (Impavido©), which is not registered in the Czech Republic. The aim of this article is to point out this imported protozoan infection and its basic clinical and laboratory features.

Keywords: visceral leishmaniasis; pancytopenia; hepatosplenomegaly; amphothericin B; miltefosin

Received: March 8, 2012; Accepted: May 2, 2012; Published: October 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Polák P, Svoboda R, Kubáčková P, Brychtová Y, Panovská A, Nohýnková E, et al.. Febrile pancytopenia and hepatosplenomegaly as leading symptoms of visceral leishmaniasis. Vnitr Lek. 2012;58(10):761-764.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Moore EM, Lockwood DN. Leishmaniasis. Clin Med 2011; 11: 492-497. Go to original source... Go to PubMed...
    2. Marty P, Pomares C, Michel G et al. Mediterranean visceral leishmaniasis. Bull Acad Natl Med 2011; 195: 181-188. Go to original source... Go to PubMed...
    3. Lahlou H, Filali AB, Alami M et al. Visceral leishmaniasis in 26 HIV-negative adults. BMC Res Notes 2011; 4: 389. Go to original source... Go to PubMed...
    4. Srividya G, Kulshrestha A, Singh R et al. Diagnosis of visceral leishmaniasis: developments over the last decade. Parasitol Res 2012; 110: 1065-1078. Go to original source... Go to PubMed...
    5. Korolová E. Leishmanióza jako profesionální tropické onemocnění. Pracov Lék 2010; 62: 20-24.
    6. Lobovská A, Nohýnková E. Nové léky proti parazitárním infekcím. Čas Lék Čes 2003; 142: 177-181.
    7. Evans KJ, Kedzierski L. Development of Vaccines against Visceral Leishmaniasis. J Trop Med 2012; 2012: 892817. Go to original source... Go to PubMed...
    8. Pitini V, Cascio A, Arrigo C et al. Visceral leishmaniasis after alemtuzumab in a patient with chronic lymphocytic leukaemia. Br J Haematol 2012; 156: 1. Go to original source... Go to PubMed...
    9. Yanamandra U, Jairam A, Shankar S et al. Visceral leishmaniasis mimicking as second line anti retroviral therapy failure. Intern Med 2011; 50: 2855-2858. Go to original source... Go to PubMed...
    10. Jawhar NM. Visceral Leishmaniasis with an Unusual Presentation in an HIV Positive Patient. Sultan Qaboos Univ Med J 2011; 11: 269-272.
    11. Varma N, Naseem S. Hematologic changes in visceral leishmaniasis/kala azar. Indian J Hematol Blood Transfus 2010; 26: 78-82. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.